Category: drug costs

The Kids Are Not OK

A new survey from the Centers for Disease Control and Prevention finds that teenagers, particularly girls, are reporting all-time high rates of violence and profound mental distress. Meanwhile, both sides in the abortion debate are anxiously waiting for a district court decision in Texas that could effectively revoke the FDA’s 22-year-old approval of the abortion pill mifepristone. Alice Miranda Ollstein of Politico, Sandhya Raman of CQ Roll Call, and Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico join KHN’s chief Washington correspondent, Julie Rovner, to discuss these issues and more.

Your Money or Your Life: Patient on $50,000-a-Week Cancer Drug Fears Leaving Behind Huge Medical Debt

When Medicare stops paying for a pricey drug that prolongs life, an Ohio man considers giving up treatment to spare his family enormous debt.

A Health-Heavy State of the Union

President Joe Biden’s 2023 State of the Union address leaned heavily on health care issues. Biden took a victory lap for recent accomplishments like capping prescription drug costs for seniors on Medicare. He also urged Congress to make permanent the boosted premium subsidies under the Affordable Care Act, and he sparred with Republicans on threats to cut Social Security and Medicare. Also this week, both sides in the abortion debate are bracing for a court decision out of Texas that could, at least temporarily, make the abortion pill mifepristone illegal nationwide. Alice Miranda Ollstein of Politico, Rachel Cohrs of Stat, and Sarah Karlin-Smith of the Pink Sheet join KHN chief Washington correspondent Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Kate Baicker of the University of Chicago about a possible middle ground in the effort to get universal health insurance coverage.

Health Policies Were a Prominent Theme in Biden’s State of the Union Speech

Our partners at PolitiFact fact-checked a range of President Joe Biden’s statements, including key health-related comments.

‘We Ain’t Gonna Get It’: Why Bernie Sanders Says His ‘Medicare for All’ Dream Must Wait

As he takes the reins of the Senate Health, Education, Labor & Pensions Committee, the independent from Vermont and implacable champion of “Medicare for All” maps out his strategy for negotiating with Republicans — and Big Pharma.

The Biggest, Buzziest Conference for Health Care Investors Convenes Amid Fears the Bubble Will Burst

This year’s JPMorgan confab, the first since covid’s chilling effect on such gatherings, was full of energy and enthusiasm. But it was also marked by questions about the future of health care investment.

States Challenge Biden to Lower Drug Prices by Allowing Imports From Canada

Colorado has joined Florida, New Hampshire, and New Mexico in seeking federal permission to import prescription drugs from Canada. President Joe Biden endorsed the approach in his 2020 campaign but has yet to approve any state plan.

KHN’s ‘What the Health?’: Congress Races the Clock

Sen. Raphael Warnock’s re-election in Georgia will give Democrats a clear-cut Senate majority for the first time in nearly a decade. Meanwhile, the current Congress has only days left to tackle major unfinished business on the health agenda, including fending off scheduled pay cuts for doctors and other health providers in the Medicare program. Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, Anna Edney of Bloomberg News, and Sandhya Raman of CQ Roll Call join KHN’s Julie Rovner to discuss these topics and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.

Employers Use Patient Assistance Programs to Offset Their Own Costs

Some insurers and employers are tapping into assistance programs meant for individual patients. The concern: Some costly drugs could be harder for patients to access.

Employers Use Patient Assistance Programs to Offset Their Own Costs

Some insurers and employers are tapping into assistance programs meant for individual patients. The concern: Some costly drugs could be harder for patients to access.